Jorge J Castillo1, Eric S Winer, Adam J Olszewski. 1. Division of Hematology and Oncology, Alpert Medical School of Brown University, Rhode Island Hospital/The Miriam Hospital, Providence, Rhode Island.
Abstract
BACKGROUND: Burkitt lymphoma (BL) is an aggressive but potentially curable lymphoma, previously described in small, single-institution studies. This study evaluated prognostic factors for survival in adult patients with BL and a potential outcome improvement over the past decade in a population-based cohort. METHODS: Adult patients with BL diagnosed between 1998 and 2009 were selected from the Surveillance, Epidemiology, and End Results (SEER) database. Prognostic factors were identified in a multivariate model for relative survival (RS), and trends in survival were evaluated using period analysis. RESULTS: The study cohort included 2284 patients, with a median age of 49 years and male predominance (2.6:1). Gastrointestinal tract and the head and neck were the most common sites of extranodal disease. Older age, black race/ethnicity, and advanced stage were associated with a worse survival. In the period analysis, trends in improved survival between 1998 and 2009 were seen, except for patients older than 60 years and black patients, whose survival did not improve. A prognostic score divided patients into 4 groups: low-risk (5-year RS: 71%), low-intermediate (5-year RS: 55%), high-intermediate (5-year RS: 41%), and high-risk (5-year RS: 29%; P < .001). CONCLUSIONS: The outcome of patients younger than 60 years with BL improved over the past decade. Age, race, and stage have a prognostic role for survival. The proposed score can help inform prognosis in newly diagnosed patients and stratify participants in future trials.
BACKGROUND:Burkitt lymphoma (BL) is an aggressive but potentially curable lymphoma, previously described in small, single-institution studies. This study evaluated prognostic factors for survival in adult patients with BL and a potential outcome improvement over the past decade in a population-based cohort. METHODS: Adult patients with BL diagnosed between 1998 and 2009 were selected from the Surveillance, Epidemiology, and End Results (SEER) database. Prognostic factors were identified in a multivariate model for relative survival (RS), and trends in survival were evaluated using period analysis. RESULTS: The study cohort included 2284 patients, with a median age of 49 years and male predominance (2.6:1). Gastrointestinal tract and the head and neck were the most common sites of extranodal disease. Older age, black race/ethnicity, and advanced stage were associated with a worse survival. In the period analysis, trends in improved survival between 1998 and 2009 were seen, except for patients older than 60 years and black patients, whose survival did not improve. A prognostic score divided patients into 4 groups: low-risk (5-year RS: 71%), low-intermediate (5-year RS: 55%), high-intermediate (5-year RS: 41%), and high-risk (5-year RS: 29%; P < .001). CONCLUSIONS: The outcome of patients younger than 60 years with BL improved over the past decade. Age, race, and stage have a prognostic role for survival. The proposed score can help inform prognosis in newly diagnosed patients and stratify participants in future trials.
Authors: Dieter Hoelzer; Jan Walewski; Hartmut Döhner; Andreas Viardot; Wolfgang Hiddemann; Karsten Spiekermann; Hubert Serve; Ulrich Dührsen; Andreas Hüttmann; Eckhard Thiel; Jolanta Dengler; Michael Kneba; Markus Schaich; Ingo G H Schmidt-Wolf; Joachim Beck; Bernd Hertenstein; Albrecht Reichle; Katarzyna Domanska-Czyz; Rainer Fietkau; Heinz-August Horst; Harald Rieder; Stefan Schwartz; Thomas Burmeister; Nicola Gökbuget Journal: Blood Date: 2014-10-30 Impact factor: 22.113
Authors: Tanya M Wildes; Laura Farrington; Cecilia Yeung; Alexandra M Harrington; Kelley V Foyil; Jingxia Liu; Friederike Kreisel; Nancy L Bartlett; Timothy S Fenske Journal: Ther Adv Hematol Date: 2014-02
Authors: S F Roy; F M Ghazawi; M Le; F Lagacé; C F Roy; E Rahme; E Savin; A Zubarev; D Sasseville; G Popradi; I V Litvinov Journal: Curr Oncol Date: 2020-05-01 Impact factor: 3.677
Authors: Andrew M Evens; Alexey Danilov; Deepa Jagadeesh; Amy Sperling; Seo-Hyun Kim; Ryan Vaca; Catherine Wei; Daniel Rector; Suchitra Sundaram; Nishitha Reddy; Yong Lin; Umar Farooq; Christopher D'Angelo; David A Bond; Stephanie Berg; Michael C Churnetski; Amandeep Godara; Nadia Khan; Yun Kyong Choi; Maryam Yazdy; Emma Rabinovich; Gaurav Varma; Reem Karmali; Agrima Mian; Malvi Savani; Madelyn Burkart; Peter Martin; Albert Ren; Ayushi Chauhan; Catherine Diefenbach; Allandria Straker-Edwards; Andreas K Klein; Kristie A Blum; Kirsten Marie Boughan; Scott E Smith; Brad M Haverkos; Victor M Orellana-Noia; Vaishalee P Kenkre; Adam Zayac; Jeremy Ramdial; Seth M Maliske; Narendranath Epperla; Parameswaran Venugopal; Tatyana A Feldman; Stephen D Smith; Andrzej Stadnik; Kevin A David; Seema Naik; Izidore S Lossos; Matthew A Lunning; Paolo Caimi; Manali Kamdar; Neil Palmisiano; Veronika Bachanova; Craig A Portell; Tycel Phillips; Adam J Olszewski; Juan Pablo Alderuccio Journal: Blood Date: 2021-01-21 Impact factor: 22.113
Authors: Massimo Dozzo; Francesca Carobolante; Pietro Maria Donisi; Annamaria Scattolin; Elena Maino; Rosaria Sancetta; Piera Viero; Renato Bassan Journal: Adolesc Health Med Ther Date: 2016-12-23